Biotechnology · Miami Beach, Florida, United States
$0.57
+6.63% (+$0.04)2026-08-25
Smart-Money SignalNeutral · 52/100— Insiders are net buyers over 90 days ($53K, 1 buy vs 0 sales)
Net Income-$5.3M
EPS$-0.29
Market Cap$19.0M
Price Performance
Historical data including institutional events
Company Profile
T
Tiago Marques
CEO & Executive Director
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The companyâs lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
- Founded
- 2020
- Employees
- 4
- Headquarters
- Miami Beach, Florida, United States
- Website
- www.pasithea.com
Peer ComparisonRevenue ($B)
▾Loading company sections...